Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a human recombinant IgG4 monoclonal antibody that targets programmed cell death-1 (PD-1) protein. PD-1 is an important immune checkpoint protein expressed on activated T-cells, B-cells, and macrophages. Binding of PD-1 to its ligands PD-L1 and PD-L2 prevent T-cell activation and cytokine production. The monoclonal antibody binds to PD-1 on T-cells and prevents its interaction with the ligands, thereby reactivating T-cells and inhibiting tumor growth. The original monoclonal antibody is approved by the FDA to treat patients with metastatic cutaneous squamous cell carcinoma (CSCC) and those patients with locally advanced CSCC but are not candidates for curative surgery or curative radiation
Biovision | A2249 | Anti-PD-1 (Cemiplimab), Human IgG4 Antibody DataSheet
Antibody Target: PD-1
Target Alternative Name: PD1, PD-1, CD279, SLEB2, hPD-1, hPD-l, hSLE1, PDCD1, HPD-L
Tag Line: The biosimilar is a human monoclonal antibody that targets PD-1, inhibits PD-1 mediated signaling, and restores immune responses against tumor cells. The original monoclonal antibody has been approved by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC)
Category: Biosimilars
Host: Recombinant
Isotype: IgG4, kappa
Species Reactivities: Human
Immunogen Sequence: Human PD-1
Accession #: DB14707
Gene ID: 5133
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
